How do you approach patients for definitive chemoradiation in locally advanced NSCLC who have severe neuropathy?

If the patient and treating physician are willing to take a calculated risk for a curative intent CRT, I would consider low dose carboplatin (per JCOG 2012 or weekly AUC 2) as chemosensitizer with close monitoring, then consolidation with durvalumab if no progression on CRT and no contra-indication ...

Carboplatin plus pemetrexed can be considered for non squamous histology. For squamous, taxanes plus platinum is generally preferred, but platinum/etoposide is an alternative listed in the NCCN guidelines.